53 results
8-K
EX-99.2
KANT
Kineta, Inc.
12 Mar 24
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
8:05am
%) Black or African American 0 (0) 1 (20) 1 (25) 0 (0) 0 (0) 0 (0) 0 (0) 2 (7) Other 0 (0) 2 (40) 0 (0) 0 (0) 0 (0) 0 (0) 1 (20) 3 (11) White 2 (100) 2
8-K
EX-99.1
KANT
Kineta, Inc.
5 Jan 24
Regulation FD Disclosure
4:30pm
/Ethnicity N (%) White Black or African American Hispanic or Latino 11 (74) 2 (13) 2 (13) Age Mean (Range) Years 62 (47-77) Characteristic Statistic
424B3
1dxqoc7lxgs hbuq
13 Nov 23
Prospectus supplement
5:28pm
8-K
EX-99.2
uiaqvyz3zq6
6 Nov 23
Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
8:30am
8-K
EX-4.3
ez1ezaig0 gx2
5 Oct 23
Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
8-K
EX-4.2
tlhtnfo59mh
5 Oct 23
Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
424B5
4aihp
5 Oct 23
Prospectus supplement for primary offering
10:47am
424B3
jkn7ht
12 Jun 23
Prospectus supplement
5:01pm
8-K
EX-4.2
pzyi6nab7mlj2vkk
21 Apr 23
Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
5:16pm
8-K
EX-4.3
9ymdlojmg9iqtn
21 Apr 23
Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
5:16pm
424B5
heplr2jjq
21 Apr 23
Prospectus supplement for primary offering
5:14pm